# 2025-21692: FDA Pushes High-Tech Tweaks to Speed Up Meds Production

2025-21692, FDA's Strategy Document on Innovative Manufacturing Technologies, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-12-01, effective 2026-01-30 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-21692
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-21692
- Title: FDA's Strategy Document on Innovative Manufacturing Technologies
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 55133
- Published: 2025-12-01
- Effective: 2026-01-30
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Pushes High-Tech Tweaks to Speed Up Meds Production

## Summary

The FDA is rolling out a new plan to speed up and support cool, high-tech ways to make medicines from 2023 to 2027. This means drug makers will get help using smarter manufacturing tools, making medicine safer and faster to produce. If you’re in the drug business, get ready for fresh rules and chances to share your thoughts starting early 2026!

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the publication of FDA's Strategy Document on Innovative Manufacturing Technologies (Strategy Document), which outlines specific actions FDA has taken and the Agency's plans for fiscal years 2023-2027 to facilitate the use of innovative manufacturing technologies. As part of the Prescription Drug User Fee Act (PDUFA) Reauthorization Performance Goals and Procedures Fiscal Years 2023-2027 (PDUFA VII), FDA committed to advance the use and implementation of innovative manufacturing. The actions described in the Strategy Document are based on lessons learned from FDA's experiences with submissions involving advanced manufacturing technologies as well as public input.

## Effects PRIA read

- Strategy to Reduce Drug Shortages: benefit, high. The FDA's Strategy Document (covering fiscal years 2023-2027) says innovative manufacturing technologies can increase product development speed, bolster supply chains, improve drug quality, and prevent drug shortages. The Agency announced the strategy in the Federal Register on January 30, 2026.
- New AMTDP Implementation Plans: benefit, medium. FDA will implement the Advanced Manufacturing Technologies Designation Program (AMTDP) and says it will incorporate feedback on eligibility criteria as part of its fiscal years 2023-2027 activities. The Strategy Document was announced in the Federal Register on January 30, 2026.
- Expanded Support via ETP and CATT: benefit, medium. FDA will continue to enhance the Center for Drug Evaluation and Research Emerging Technology Program (ETP) and the Center for Biologics Evaluation and Research Advanced Technologies Team (CATT) to support use of innovative manufacturing technologies during fiscal years 2023-2027. The Strategy Docum…
- International Harmonization Efforts: benefit, low. FDA says it will continue to identify opportunities for international harmonization of regulatory expectations to support wider adoption of advanced manufacturing technologies as part of its 2023-2027 strategy. The Strategy Document announcement date is January 30, 2026.
- FDA Staff Training on Advanced Manufacturing: benefit, low. The Strategy Document says FDA will support training in advanced manufacturing for FDA regulatory staff as part of activities for fiscal years 2023-2027. The document was announced in the Federal Register on January 30, 2026.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-21692 on federalregister.gov](https://www.federalregister.gov/documents/2025/12/01/2025-21692/fdas-strategy-document-on-innovative-manufacturing-technologies)
- [2025-21692 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-12-01/pdf/2025-21692.pdf)

## Related
- [Previous: 2025-21691, Slag Pots From China; Determinations](https://policyrisk.com/federal-register/2025-21691)
- [Next: 2025-21693, Initiation of Five-Year (Sunset) Reviews](https://policyrisk.com/federal-register/2025-21693)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-21692 (as of 2026-06-08).
